No, dicyclomine should NOT be given intravenously
Dicyclomine is not approved for intravenous administration and IV use is associated with serious thrombotic complications. The FDA-approved routes for dicyclomine are oral and intramuscular only 1.
Critical Safety Concerns
Thrombosis Risk
A documented case report demonstrates that inadvertent IV administration of dicyclomine resulted in both non-occlusive axillary vein thrombosis and occlusive superficial basilic vein thrombosis 2. The mechanism involves:
- M3 receptor blockade inhibiting nitric oxide activation, promoting clot formation
- When combined with other medications (like ketorolac in the reported case), the pro-thrombotic effect is amplified
- The Naranjo algorithm assessment indicated "possible" causality for this drug-induced adverse event 2
FDA-Approved Routes Only
The FDA drug label explicitly describes only oral and intramuscular formulations 1. There is no IV formulation approved, and no dosing guidance exists for IV administration because this route was never studied or validated for safety.
What to Do Instead
For acute situations requiring immediate anticholinergic/antispasmodic effect:
- Use intramuscular dicyclomine if parenteral administration is necessary
- Consider alternative medications with established IV safety profiles for the specific indication (e.g., IV anticholinergics like glycopyrrolate for secretion control, or IV antispasmodics appropriate for the clinical scenario)
Common Pitfall to Avoid
The most dangerous error is mixing dicyclomine with other IV medications in the same syringe and inadvertently administering it intravenously 2. Healthcare systems should implement barcode medication administration safeguards to prevent this medication error, as the consequences include potentially life-threatening thrombotic events requiring anticoagulation therapy.
If IV administration has already occurred: Monitor closely for signs of thrombosis (pain, swelling, erythema at injection site or distal extremity), obtain vascular ultrasound if concerning findings develop, and initiate anticoagulation if thrombosis is confirmed 2.